arXiv:2606.14159v1 Announce Type: new Abstract: Protein-ligand binding affinity (PLA) prediction is critical in drug discovery. Despite the notable advancements in machine learning-based approaches, existing methods struggle to jointly characterize local geometric organization and globally coordinated cross-molecular interactions, limiting their ability to model complex binding mechanisms. Here, we propose RicciBind, a geometric representation framework that integrates curvature-guided hierarchical structure learning with optimal transport (OT)-based cross-domain alignment to model molecular i
Advancements in geometric deep learning and computational power are enabling more sophisticated approaches to molecular modeling, addressing the limitations of prior machine learning methods in drug discovery.
Improved protein-ligand binding affinity prediction accelerates drug discovery workflows, reducing R&D costs and time-to-market for new therapeutics and potentially enabling the discovery of novel drug candidates.
The ability to accurately model complex binding mechanisms using geometric representations will lead to more efficient and targeted drug design, shifting from high-throughput screening to computational lead optimization.
- · Pharmaceutical companies
- · Biotechnology startups
- · AI/ML drug discovery platforms
- · Patients
- · Traditional drug screening methods
- · Companies relying on brute-force R&D paradigms
Faster identification of promising drug candidates for various diseases.
Reduced incidence of clinical trial failures due to better preclinical prediction of drug efficacy and specificity.
The development of 'designer drugs' tailored with unprecedented precision for individual patient genomic profiles.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG